John Adams

Patients know about pharmacare: let’s listen to them on Bill C-64

• Patient groups’ involvement should be built into the program, not just a one-time pre-consultation.

Opinion | BY JOHN ADAMS, LINDA WILHELM | June 3, 2024

Patients know about pharmacare: let’s listen to them on Bill C-64

Opinion | BY JOHN ADAMS, LINDA WILHELM | June 3, 2024

• Patient groups’ involvement should be built into the program, not just a one-time pre-consultation.

Patients know about pharmacare: let’s listen to them on Bill C-64

Opinion | BY JOHN ADAMS, LINDA WILHELM | June 3, 2024

• Patient groups’ involvement should be built into the program, not just a one-time pre-consultation.

Government hostility to biopharmaceutical industry reduces access to innovative drugs

• Developers bring new drugs to Canada later than in other nations. Some aren’t launched here at all. The result is that Canadians who need

Opinion | BY NIGEL RAWSON, JOHN ADAMS | November 15, 2023

Government hostility to biopharmaceutical industry reduces access to innovative drugs

Opinion | BY NIGEL RAWSON, JOHN ADAMS | November 15, 2023

• Developers bring new drugs to Canada later than in other nations. Some aren’t launched here at all. The result is that Canadians who need

Government hostility to biopharmaceutical industry reduces access to innovative drugs

Opinion | BY NIGEL RAWSON, JOHN ADAMS | November 15, 2023

• Developers bring new drugs to Canada later than in other nations. Some aren’t launched here at all. The result is that Canadians who need

More Stories